Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

Published:2015-11-03 Issue:12 Volume:125 Page:4559-4571
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Goldstein Rebecca L.,Yang Shao Ning,Taldone Tony,Chang Betty,Gerecitano John,Elenitoba-Johnson Kojo,Shaknovich Rita,Tam Wayne,Leonard John P.,Chiosis Gabriela,Cerchietti Leandro,Melnick Ari

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference27 articles.

1. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas

4. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

5. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoproteomics and Cancer Management;Pharmacoproteomics;2024

2. SIRT1 and HSP90α feed-forward circuit safeguards chromosome segregation integrity in diffuse large B cell lymphomas;Cell Death & Disease;2023-10-11

3. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells;Blood;2023-09-21

4. Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches;Cancers;2023-02-03

5. The penalty of stress ‐ Epichaperomes negatively reshaping the brain in neurodegenerative disorders;Journal of Neurochemistry;2021-10-31